«Clinical Commissioning policy: Amifampridine phosphate for the treatment of LambertEaston Myasthenic Syndrome Reference: NHS England: 16009/P ...»
2) Is amifampridine phosphate cost effective in adult patients with confirmed Lambert-Eaton Myasthenic Syndrome?
No studies reporting on the cost-effectiveness of amifampridine phosphate were identified in the literature search.
The Cochrane Review (Keogh et al., 2011) provided a brief commentary on the costbenefit of 3, 4-DAP (base) versus 3, 4-DAP (phosphate). Using an average dose of 40mg daily, an average price for 3,4-DAP base of £1/tablet and an average price for 3,4-DAP phosphate of £2,017/100 tablets, the authors estimated a yearly cost per person of £730 for the base versus £29,448 for the phosphate formulation. This was
not a cost-effectiveness analysis, but rather a commentary on the increased pricing associated with the phosphate formulation.
6 Documents which have informed this Policy NHS England Clinical Commissioning Policy Statement: Amifampridine (Firdapse) for Lambert Easton Myasthenic Syndrome (LEMS). Published date: April 2013.
Reference : NHSCB/D04/PS/a 7 Date of Review This document will be reviewed when information is received which indicates that the policy requires revision.
References Flet L, Polard E, Guillard O et al. 3,4-Diaminopyridine safety in clinical practice: an observational,retrospective cohort study.. Journal of Neurology 2010;257:937-46 2010.
Keogh M, Sedehizadeh S, Maddison P.. Treatment for Lambert-Eaton myasthenic syndrome.. Cochrane Database Syst Rev. 2011;(2):CD003279.
NHS England Clinical Commissioning Policy Statement: Amifampridine (Firdapse) for Lambert Easton Myasthenic Syndrome (LEMS). Published date: April 2013.
Reference : NHSCB/D04/PS/a Sedehizadeh, Saam; Keogh, Michael; Maddison, Paul. The use of aminopyridines in